Bluelinea Société Anonyme (ALBLU.PA)
EUR 0.63
(-6.67%)
EUR 0.63
(-6.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.62 Million EUR | 99.9% |
| 2022 | -1.54 Million EUR | 53.26% |
| 2021 | -3.3 Million EUR | -22.29% |
| 2020 | -2.7 Million EUR | 3.15% |
| 2019 | -2.78 Million EUR | -1.8% |
| 2018 | -2.73 Million EUR | -91476.82% |
| 2017 | -2991.37 EUR | 9.72% |
| 2016 | -3313.44 EUR | -189.21% |
| 2015 | -1145.69 EUR | 99.93% |
| 2014 | -1.61 Million EUR | -97.72% |
| 2013 | -815.8 Thousand EUR | -124.47% |
| 2012 | -363.43 Thousand EUR | -105.87% |
| 2011 | -176.53 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.22 Million EUR | 0.0% |
| 2023 Q2 | -1.15 Million EUR | 0.0% |
| 2023 FY | -1.62 Million EUR | -4.93% |
| 2023 Q4 | -463 Thousand EUR | 0.0% |
| 2022 Q4 | -1.01 Million EUR | 0.0% |
| 2022 FY | -1.54 Million EUR | 53.26% |
| 2022 Q2 | -524.55 Thousand EUR | 0.0% |
| 2021 FY | -3.3 Million EUR | -22.29% |
| 2021 Q4 | -1.59 Million EUR | 0.0% |
| 2021 Q2 | -1.7 Million EUR | 0.0% |
| 2020 Q2 | -1.34 Million EUR | 0.0% |
| 2020 FY | -2.7 Million EUR | 3.15% |
| 2020 Q4 | -1.35 Million EUR | 0.0% |
| 2019 Q4 | -1530.60 EUR | 0.0% |
| 2019 Q2 | -1258.17 EUR | 0.0% |
| 2019 FY | -2.78 Million EUR | -1.8% |
| 2018 Q2 | -1.19 Million EUR | 0.0% |
| 2018 Q4 | -1.54 Million EUR | 0.0% |
| 2018 FY | -2.73 Million EUR | -91476.82% |
| 2017 Q4 | -1147.17 EUR | 0.0% |
| 2017 FY | -2991.37 EUR | 9.72% |
| 2017 Q2 | -1844.20 EUR | 0.0% |
| 2016 FY | -3313.44 EUR | -189.21% |
| 2016 Q2 | -1477.29 EUR | 0.0% |
| 2016 Q4 | -1836.15 EUR | 0.0% |
| 2015 FY | -1145.69 EUR | 99.93% |
| 2015 Q2 | -1040.32 EUR | 0.0% |
| 2015 Q4 | -105.38 EUR | 0.0% |
| 2014 Q1 | -395.09 Thousand EUR | 0.0% |
| 2014 Q2 | -919.21 EUR | 99.77% |
| 2014 Q4 | -693.83 EUR | 99.82% |
| 2014 FY | -1.61 Million EUR | -97.72% |
| 2014 Q3 | -395.09 Thousand EUR | -42882.23% |
| 2013 Q3 | -208.7 Thousand EUR | 0.0% |
| 2013 Q1 | -208.7 Thousand EUR | 0.0% |
| 2013 Q4 | -395.09 Thousand EUR | -89.31% |
| 2013 FY | -815.8 Thousand EUR | -124.47% |
| 2013 Q2 | -208.7 Thousand EUR | 0.0% |
| 2012 FY | -363.43 Thousand EUR | -105.87% |
| 2012 Q2 | -120.57 Thousand EUR | 0.0% |
| 2012 Q4 | -208.7 Thousand EUR | -73.1% |
| 2012 Q1 | -120.57 Thousand EUR | 0.0% |
| 2012 Q3 | -120.57 Thousand EUR | 0.0% |
| 2011 Q2 | -44.13 Thousand EUR | 0.0% |
| 2011 FY | -176.53 Thousand EUR | 0.0% |
| 2011 Q3 | -44.13 Thousand EUR | 0.0% |
| 2011 Q1 | -44.13 Thousand EUR | 0.0% |
| 2011 Q4 | -120.57 Thousand EUR | -173.19% |
| 2010 Q4 | -44.13 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Affluent Medical SA | -15.65 Million EUR | 89.651% |
| Carmat SA | -53.86 Million EUR | 96.993% |
| Diagnostic Medical Systems S.A. | -4.94 Million EUR | 67.246% |
| Euromedis Groupe | 13.11 Million EUR | 112.357% |
| Eurobio Scientific Société anonyme | 4.83 Million EUR | 133.506% |
| Ikonisys S.A. | -2.26 Million EUR | 28.56% |
| Implanet S.A. | -6.67 Million EUR | 75.734% |
| Median Technologies SA | -22.98 Million EUR | 92.951% |
| SpineGuard SA | -4.18 Million EUR | 61.276% |
| Theraclion SA | -3.67 Million EUR | 55.918% |
| Euroapi S.A. | -189.7 Million EUR | 99.146% |
| Guerbet SA | 23.86 Million EUR | 106.788% |